1. Home
  2. CASH vs NUVB Comparison

CASH vs NUVB Comparison

Compare CASH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pathward Financial Inc.

CASH

Pathward Financial Inc.

HOLD

Current Price

$82.52

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.76

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CASH
NUVB
Founded
1954
2018
Country
United States
United States
Employees
N/A
307
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
CASH
NUVB
Price
$82.52
$5.76
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$107.50
$11.38
AVG Volume (30 Days)
181.3K
4.3M
Earning Date
04-22-2026
05-04-2026
Dividend Yield
0.23%
N/A
EPS Growth
18.88
N/A
EPS
4.89
N/A
Revenue
$839,894,000.00
N/A
Revenue This Year
$7.56
$203.82
Revenue Next Year
$6.02
$58.18
P/E Ratio
$16.78
N/A
Revenue Growth
11.29
N/A
52 Week Low
$65.93
$1.87
52 Week High
$101.26
$9.75

Technical Indicators

Market Signals
Indicator
CASH
NUVB
Relative Strength Index (RSI) 49.91 69.08
Support Level $81.14 $4.13
Resistance Level $84.62 $6.06
Average True Range (ATR) 2.28 0.38
MACD 0.44 0.10
Stochastic Oscillator 59.40 96.14

Price Performance

Historical Comparison
CASH
NUVB

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: